A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Pfizer
- Study ID
- NCT06629779
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- PF-06821497 — DRUGOral continuous
- Placebo — DRUGOral continuous
- Enzalutamide — DRUGOral continuous
Study Details
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Key Dates
- Start date
- Oct 22, 2024
- Status verified
- Jun 2026
- Primary completion
- Dec 2, 2026
- Completion
- Nov 30, 2028
Study Design
- Enrollment
- 900 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm AParticipants will receive PF-06821497 (875 mg) BID (twice daily) + enzalutamide 160 mg QD (once daily)
- Active Comparator: Arm BParticipants will receive Placebo BID (twice daily) + enzalutamide 160 mg QD (once daily)
Primary Outcome Measure
Radiographic Progression Free Survival (rPFS) [ Time Frame: Randomization up to approximately 3 years ]
Central Contacts
- Pfizer CT.gov Call Center1-800-718-1021
Locations (44)
Find similar trials in Chandler, AZ
By condition
By specialty
Related Studies
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerPHASE2 · Recruiting · Zenith Epigenetics · Los Angeles, California
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerPHASE1/PHASE2 · Recruiting · Vadim S Koshkin · San Francisco, California